Skip to main content
Premium Trial:

Request an Annual Quote

BGI Oseq Hereditary Cancer Panel

BGI Americas has launched the Oseq Hereditary Cancer Panel (HGP), an assay that is designed to identify known and emerging tumor biomarkers for 17 cancer types and to support clinical trials of anti-cancer drugs. The panel, which runs on the MGISEQ-2000, Illumina HiSeq 2500, and Illumina HiSeq 4000 systems, looks for germline variants in the exons of up to 115 target genes. It covers mutations in the BRCA 1/2 genes that are contained in the proprietary BGI Hereditary Cancer Genetic Database v1.0, which integrates results from more than 30,000 clinical tests. The assay has been clinically validated in BGI's CAP-accredited and CLIA-certified Hong Kong laboratory and is currently being reviewed for accelerated IVD approval by the China National Medical Products Administration.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.